share_log
  • Headlines
  • Reported Saturday, Pfizer's BRAFTOVI + MEKTOVI Shows Long-Term Efficacy In BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer Patients After Three-Year Follow-Up

Reported Saturday, Pfizer's BRAFTOVI + MEKTOVI Shows Long-Term Efficacy In BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer Patients After Three-Year Follow-Up

Benzinga ·  Sep 16 16:17
  • BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration of response and progression-free survival in treatment-naïve patients compared to historical outcomes
  • Results support BRAFTOVI + MEKTOVI as a standard of care option for this population
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated